Core Insights - The trend of consumerization in pharmaceutical consumption is leading to increased patient involvement in treatment decisions, with safety and brand reputation becoming the primary considerations when purchasing medications [1] - The innovative non-hormonal drug, Zeli Mei Ben Wei Mo De Cream, is leading the market upgrade in the treatment of atopic dermatitis (eczema) [1] Industry Overview - Approximately 70 million eczema patients in China, with over 90% requiring topical treatments [2] - Traditional treatments have limitations such as limited efficacy, significant side effects, and a tendency for relapse after discontinuation [2] - Zeli Mei is the first globally approved aromatic hydrocarbon receptor modulator for eczema treatment in children over 2 years and adults, addressing the core issues of traditional therapies [2] Clinical Efficacy - Zeli Mei has shown a significant improvement in treatment outcomes, with nearly 60% of patients experiencing deep itch relief after 8 weeks, and over 80% efficacy in children [2] - In a Chinese Phase III clinical trial, 70% of patients remained relapse-free for 10 months after stopping treatment [2] - Clinical cases demonstrate rapid symptom relief, with 73% of pediatric patients showing significant improvement after treatment [3]

Core Insights - The market demand for eczema treatments is evolving, with a shift towards non-hormonal innovative drugs like Zhilimei (Bimekizumab), which are gaining traction due to their efficacy and safety profile [1][2][5] Group 1: Market Trends - There is a notable trend of "consumerization" in the pharmaceutical sector, where patients are increasingly involved in treatment decisions, prioritizing safety and brand reputation [6][7] - The demand for non-hormonal treatments is rising as traditional hormonal therapies face limitations due to side effects and patient fears [1][6] Group 2: Product Overview - Zhilimei is the first innovative drug approved for treating eczema in children over two years old, utilizing a novel mechanism targeting the aryl hydrocarbon receptor (AhR) [2][4] - Clinical trials indicate that nearly 60% of patients experience significant itch relief after eight weeks of treatment, with over 80% efficacy in children [2][3] Group 3: Clinical Validation - The 2025 Expert Consensus on Eczema Treatment in China highlights Zhilimei as a key treatment option, emphasizing its dual benefits of inflammation suppression and skin barrier repair [2][4] - Real-world patient feedback shows significant improvements in symptoms, with over 73% of children experiencing resolution of eczema symptoms after using Zhilimei [3][5] Group 4: Sales and Market Performance - Zhilimei achieved significant sales growth, with a 500% increase in transaction volume during the recent Double 11 shopping festival on JD.com [6][7] - The product has been recognized in the 2025 Shanghai Biopharmaceutical "New and Excellent Drug" directory, reflecting its acceptance across various stakeholders [7]